Indaptus Therapeutics
Yahoo Finance • 11 months ago
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. “We c... Full story
Yahoo Finance • 11 months ago
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to generate a stabilized package of immune ag... Full story
Yahoo Finance • last year
Indaptus Therapeutics to Present at the LD Micro Main Event XVI
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the LD Micro Main Event XVI. The conference is... Full story
Yahoo Finance • last year
Registration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus’ CEO, Jeffrey Meckler will present at Tribe Public’s Webinar Presentation and Q&A Event titled “Immunotherapy Reimagined." Th... Full story
Yahoo Finance • last year
Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20
NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) announces dosing of the first patient in the second cohort of patients to receive a single dose of Decoy20 in the INDP-... Full story
Yahoo Finance • last year
Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investm... Full story
Yahoo Finance • last year
Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We have... Full story
Yahoo Finance • last year
Indaptus Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference
NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced today that CEO Jeffrey A. Meckler w... Full story
Yahoo Finance • last year
Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. “Followin... Full story
Yahoo Finance • last year
Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform
NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that it has received notice of... Full story
Yahoo Finance • last year
Indaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit
NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces t... Full story
Yahoo Finance • last year
Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023
NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that CEO Jeffrey A. Meckler... Full story
Yahoo Finance • last year
Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces it has received a patent all... Full story
Yahoo Finance • 2 years ago
Indaptus Therapeutics to Present at the Investor Summit Conference
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that it will participate at... Full story
Yahoo Finance • 2 years ago
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a corpor... Full story
Yahoo Finance • 2 years ago
Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Company Remains On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Q4 2022 NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today... Full story
Yahoo Finance • 2 years ago
Indaptus Therapeutics to Present at the LD Micro Main Event XV
NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the LD Micro Main Event XV. The conference is be... Full story
Yahoo Finance • 2 years ago
Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the 24th Annual H.C. Wainwright Global Investme... Full story
Yahoo Finance • 2 years ago
Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
U.S. Food and Drug Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in 2022 NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE... Full story
Yahoo Finance • 2 years ago
Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the... Full story
